Helicobacter pylori modulates cyclooxygenase‑2 and 15‑hydroxy prostaglandin dehydrogenase in gastric cancer

Zhao,Jianqiu; Wen,Shujun; Wang,Xingfen; Zhang,Zhiguang

doi:10.3892/ol.2017.6843

Helicobacter pylori modulates cyclooxygenase‑2 and 15‑hydroxy prostaglandin dehydrogenase in gastric cancer

Authors:
- Jianqiu Zhao
- Shujun Wen
- Xingfen Wang
- Zhiguang Zhang
View Affiliations

Affiliations: Department of Gastroenterology, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China, Department of Pathology, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China
Published online on: August 28, 2017 https://doi.org/10.3892/ol.2017.6843
Pages: 5519-5525

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Persistent infection with Helicobacter pylori may contribute to the carcinogenesis of gastric cancer through modulating local prostaglandin E2 (PGE2) levels. Cyclooxygenase‑2 (COX‑2) and 15‑hydroxy prostaglandin dehydrogenase (15‑PGDH) are two key enzymes that regulate PGE2 synthesis and inactivation, respectively. The present study was designed to investigate the expression of COX‑2 and 15‑PGDH in gastric cancer specimens (n=66) in comparison to that of control specimens (n=70) and, furthermore, to semi‑quantitatively assess the level of COX‑2 and 15‑PGDH mRNA and protein in tissues with or without H. pylori infection by reverse transcription‑polymerase chain reaction and immunohistochemistry, respectively. It was revealed that COX‑2 was expressed in almost all gastric cancer specimens infected with H. pylori (32 out of 33 specimens), but it was also expressed in 2/3 gastric cancers without H. pylori infection (22 out of 33 specimens). By contrast, COX‑2 was expressed in <1/6 control subjects regardless of H. pylori infection. Furthermore, 15‑PGDH was expressed in control samples but significantly downregulated in gastric cancer specimens. H. pylori infection resulted in slight inhibition of 15‑PGDH in control subjects, but significant inhibition of 15‑PGDH mRNA expression and protein synthesis in the gastric cancer specimens. These findings indicated that COX‑2 and 15‑PGDH, the two enzymes that regulate PGE2 levels, were significantly altered in gastric cancer, and that H. pylori may contribute to gastric carcinogenesis through modulating COX‑2 and 15‑PGDH mRNA expression and protein synthesis.

View Figures

View References

1	Houghton J and Wang TC: Helicobacter pylori and gastric cancer: A new paradigm for inflammation-associated epithelial cancers. Gastroenterology. 128:1567–1578. 2005. View Article : Google Scholar : PubMed/NCBI
2	Ernst PB, Peura DA and Crowe SE: The translation of Helicobacter pylori basic research to patient care. Gastroenterology. 130:188–206. 2006. View Article : Google Scholar : PubMed/NCBI
3	Liu N, Wu Q, Wang Y, Sui H, Liu X, Zhou N, Zhou L, Wang Y, Ye N, Fu X, et al: Helicobacter pylori promotes VEGF expression via the p38 MAPKmediated COX2PGE2 pathway in MKN45 cells. Mol Med Rep. 10:2123–2129. 2014. View Article : Google Scholar : PubMed/NCBI
4	Fu S, Ramanujam KS, Wong A, Fantry GT, Drachenberg CB, James SP, Meltzer SJ and Wilson KT: Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology. 116:1319–1329. 1999. View Article : Google Scholar : PubMed/NCBI
5	Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C and Kaidi A: The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
6	Fujino H, Xu W and Regan JW: Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem. 278:12151–12156. 2003. View Article : Google Scholar : PubMed/NCBI
7	Sheng H, Shao J, Washington MK and DuBois RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 276:18075–18081. 2001. View Article : Google Scholar : PubMed/NCBI
8	Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H and Tarnawski AS: PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun. 286:923–928. 2001. View Article : Google Scholar : PubMed/NCBI
9	Tai HH: Prostaglandin catabolic enzymes as tumor suppressors. Cancer Metastasis Rev. 30:409–417. 2011. View Article : Google Scholar : PubMed/NCBI
10	Na HK, Park JM, Lee HG, Lee HN, Myung SJ and Surh YJ: 15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy. Biochem Pharmacol. 82:1352–1360. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ryu YM, Myung SJ, Park YS, Yang DH, Song HJ, Jeong JY, Lee SM, Song M, Kim DH, Lee HJ, et al: Inhibition of 15-hydroxyprostaglandin dehydrogenase by Helicobacter pylori in human gastric carcinogenesis. Cancer Prev Res (Phila). 6:349–359. 2013. View Article : Google Scholar : PubMed/NCBI
12	Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, et al: 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA. 103:12098–12102. 2006. View Article : Google Scholar : PubMed/NCBI
13	Sitas F: Twenty five years since the first prospective study by Forman et al (1991) on Helicobacter pylori and stomach cancer risk. Cancer Epidemiol. 41:159–164. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhang L, Wu WK, Gallo RL, Fang EF, Hu W, Ling TK, Shen J, Chan RL, Lu L, Luo XM, et al: Critical role of antimicrobial peptide cathelicidin for controlling Helicobacter pylori survival and infection. J Immunol. 196:1799–1809. 2016. View Article : Google Scholar : PubMed/NCBI
15	Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N and Sibley RK: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 325:1127–1131. 1991. View Article : Google Scholar : PubMed/NCBI
16	Peek RM Jr and Blaser MJ: Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2:28–37. 2002. View Article : Google Scholar : PubMed/NCBI
17	Tanigawa T, Watanabe T, Hamaguchi M, Sasaki E, Tominaga K, Fujiwara Y, Oshitani N, Matsumoto T, Higuchi K and Arakawa T: Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: Possible involvement of PGE2. Am J Physiol Gastrointest Liver Physiol. 286:G148–G156. 2004. View Article : Google Scholar : PubMed/NCBI
18	Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D and Tarnawski AS: Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 8:289–293. 2002. View Article : Google Scholar : PubMed/NCBI
19	Society of Stomach Cancer of Chinese Anti-Cancer Association, ; Society of Pathology of Chinese Anti-Cancer Association; Chinese Society of Clinical Oncology, . Chinese expert consensus on the molecular-targeted therapy for HER-2-positive advanced gastric cancer. Zhonghua Zhong Liu Za Zhi. 35:315–319. 2013.(In Chinese). PubMed/NCBI
20	Ding Y, Tong M, Liu S, Moscow JA and Tai HH: NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis. 26:65–72. 2005. View Article : Google Scholar : PubMed/NCBI
21	Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY and Koeffler HP: 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 66:7818–7823. 2006. View Article : Google Scholar : PubMed/NCBI
22	Pham H, Chen M, Li A, King J, Angst E, Dawson DW, Park J, Reber HA, Hines OJ and Eibl G: Loss of 15-hydroxyprostaglandin dehydrogenase increases prostaglandin E2 in pancreatic tumors. Pancreas. 39:332–339. 2010. View Article : Google Scholar : PubMed/NCBI
23	Tseng-Rogenski S, Gee J, Ignatoski KW, Kunju LP, Bucheit A, Kintner HJ, Morris D, Tallman C, Evron J, Wood CG, et al: Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression. Am J Pathol. 176:1462–1468. 2010. View Article : Google Scholar : PubMed/NCBI
24	Song HJ, Myung SJ, Kim IW, et al: 15-hydroxyprostaglandin dehydrogenase is downregulated and exhibits tumor suppressor activity in gastric cancer. Cancer Invest. 29:257–265. 2011. View Article : Google Scholar : PubMed/NCBI
25	Oshima H, Oshima M, Inaba K and Taketo MM: Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 23:1669–1678. 2004. View Article : Google Scholar : PubMed/NCBI
26	Sierra JC, Hobbs S, Chaturvedi R, Yan F, Wilson KT, Peek RM Jr and Polk DB: Induction of COX-2 expression by Helicobacter pylori is mediated by activation of epidermal growth factor receptor in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol. 305:G196–G203. 2013. View Article : Google Scholar : PubMed/NCBI
27	Slomiany BL and Slomiany A: Induction in gastric mucosal prostaglandin and nitric oxide by Helicobacter pylori is dependent on MAPK/ERK-mediated activation of IKK-beta and cPLA2: Modulatory effect of ghrelin. Inflammopharmacology. 21:241–251. 2013. View Article : Google Scholar : PubMed/NCBI
28	Sun WH, Yu Q, Shen H, Ou XL, Cao DZ, Yu T, Qian C, Zhu F, Sun YL, Fu XL and Su H: Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World J Gastroenterol. 10:2809–2813. 2004. View Article : Google Scholar : PubMed/NCBI
29	Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, et al: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 355:885–895. 2006. View Article : Google Scholar : PubMed/NCBI